{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:03:54Z","timestamp":1789707834396,"version":"4.0.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Trophoblast cell surface antigen 2 (Trop-2), a transmembrane glycoprotein abundantly expressed in breast cancer tissues, has become a prominent target in precision cancer therapy, with Sacituzumab govitecan (SG) being the first antibody-drug conjugate (ADC) designed against it. Breast cancer, the most common malignancy in women, has a prognosis severely compromised by recurrence and metastasis. This meta-analysis of randomized controlled trials (RCTs) aims to systematically evaluate the clinical benefits and safety of SG in treating metastatic breast cancer (mBC). (\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261347978<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was carried out in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov, with a search period extending up to December 1, 2025, for RCTs examining the therapeutic efficacy and safety of SG for mBC. All statistical analyses were conducted using Review Manager (version 5.4), with pooled effect sizes computed using a fixed-effect or random-effects model depending on the degree of heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of four phase III, multicenter, open-label RCTs were included in this systematic review. The experimental arm received sacituzumab govitecan (SG), and the control arm received chemotherapy. The efficacy analysis included 1,900 patients with metastatic breast cancer (mBC) (SG arm,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009952; control arm,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009948), and the safety analysis included 1,879 patients (SG arm,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009966; control arm,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009913). Compared with chemotherapy, SG significantly prolonged progression-free survival (PFS) (HR 0.58, 95% CI 0.46\u20130.72) and overall survival (OS) (HR 0.62, 95% CI 0.45\u20130.86). In addition, SG showed a trend toward higher objective response rate (ORR) and partial response (PR) rate, though neither difference was statistically significant; however, the complete response (CR) rate was significantly higher with SG (RR 1.94, 95% CI 1.11\u20133.38). The any-grade adverse events (AEs) with the highest reported incidence were neutropenia, followed by nausea, diarrhea, alopecia, anemia, and fatigue. Notably, treatment with SG was linked to a significantly elevated rate of grade \u22653 neutropenia (RR 1.24, 95% CI 1.06\u20131.46) and diarrhea (RR 8.46, 95% CI 1.48\u201348.51).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SG may provide clinical benefit and favorable effects on HRQoL in mBC; however, its more definitive clinical advantages and the magnitude of benefit still require further validation. In addition, SG is associated with toxicities including neutropenia and diarrhea, warranting appropriate prophylactic measures in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261347978<\/jats:ext-link>\n                      , PROSPERO CRD420261347978.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1948167","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:32:43Z","timestamp":1789705963000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safety"],"prefix":"10.3389","volume":"13","author":[{"given":"Zepeng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Beijing University of Chinese Medicine Third Affiliated Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shewen","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Beijing University of Chinese Medicine Third Affiliated Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Beijing University of Chinese Medicine Third Affiliated Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Beijing University of Chinese Medicine Third Affiliated Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3322\/caac.70011","article-title":"\u00a0Cancer treatment and survivorship statistics, 2025","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","first-page":"117863","DOI":"10.1016\/j.ejmech.2025.117863","article-title":"Evolution of TROP2: biological insights and clinical applications","volume":"296","author":"Zhang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"Kopp","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00228-025-03876-w","article-title":"A meta-analysis and systematic review of the first trop-2-targeting antibody-drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer","volume":"81","author":"Wang","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"103853","DOI":"10.1016\/j.breast.2024.103853","article-title":"Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis","volume":"79","author":"Dacoregio","year":"2025","journal-title":"Breast"},{"key":"B18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody-drug conjugates in solid tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu Rev Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3390\/cancers13102308","article-title":"Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients: the need for a standardized approach","volume":"13","author":"Clarijs","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"115451","DOI":"10.1016\/j.ejca.2025.115451","article-title":"Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"222","author":"Jordan","year":"2025","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: aSCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1679648","DOI":"10.3389\/fimmu.2025.1679648","article-title":"Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials","volume":"16","author":"Piekarz","year":"2026","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"108296","DOI":"10.1016\/j.pharmthera.2022.108296","article-title":"Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer","volume":"239","author":"Liu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast"},{"key":"B34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e33232","DOI":"10.1016\/j.heliyon.2024.e33232","article-title":"Generation of anti-SN38 antibody for loading efficacy and therapeutic monitoring of SN38-containing therapeutics","volume":"10","author":"Zarnoosheh Farahani","year":"2024","journal-title":"Heliyon"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"106905","DOI":"10.1016\/j.esmoop.2026.106905","article-title":"Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia","volume":"11","author":"Rugo","year":"","journal-title":"ESMO Open"},{"key":"B38","doi-asserted-by":"publisher","first-page":"102672","DOI":"10.1016\/j.ctrv.2023.102672","article-title":"Breaking barriers in triple negative breast cancer (TNBC) - unleashing the power of antibody-drug conjugates (ADCs)","volume":"123","author":"Dri","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"TPS1106","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1106","article-title":"SACI-IO TNBC: randomized phase II trial of sacituzumab govitecan \u00b1 pembrolizumabin PD-L1- metastatic triple-negative breast cancer","volume":"39","author":"Garrido-Castro","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1948167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:32:56Z","timestamp":1789705976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1948167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":40,"alternative-id":["10.3389\/fmed.2026.1948167"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1948167","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1948167"}}